All studies
Oncology · Registry · England
Chesanga 2025
Prostate cancer
PPSuperiorityAcademia, Industry2/5 disclosures
Comparisons
1
In the analysis
0
1 withheld
Target trials
1
Emulations reported
1
2 treatments
Design and methods
- Estimand
- PP
- Design hypothesis
- Superiority
- Matching / weighting
- Clone-censor-weight
- Analysis method
- Landmark clone-censor-weight analysis with bootstrap
- Missing data
- Complete case
- DAG
- No
- QBA
- No
Data and sample
- Data type
- Registry
- Data sources
- 4
- Geography
- England
- Eligible sample
- 2690
- Treated
- 2201
- Control
- 489
- Emulations
- 1
- Treatments compared
- 2
Transparency
- Protocol
- No pre-registration
- Preprint
- No preprint
- Data availability
- Unavailable
- Code availability
- Unavailable
- Conflicts of interest
- Declared: Industry
- COI institutions
- AstraZeneca and other disclosed relationships
- Funding
- Declared: Public, Private
- Funders
- ESRC; AstraZeneca PhD studentship; UKRI; HQIP; NHS England; Welsh Government
The 0-5 count records which disclosures are present. It is not a quality score: a data link does not establish that the data are reusable.
Provenance
- Review key
- 2025_Chesanga_ProstateCancer
- DOI
- 10.1016/j.jclinepi.2025.111767
- Affiliations
- London School of Hygiene and Tropical Medicine; Royal College of Surgeons of England; AstraZeneca
- Sector
- Academia, Industry
- Target trials (study level)
- PR07
- Registration
- NCT00002633